I. Policy: Convection-Enhanced Drug Delivery

II. Purpose/Objective:
   To provide a policy of coverage regarding Convection-Enhanced Drug Delivery

III. Responsibility:
   A. Medical Directors
   B. Medical Management

IV. Required Definitions
   1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
   2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
   3. Devised – the date the policy was implemented.
   4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
   5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions
   Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:
      a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
      b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
      c. in accordance with current standards of good medical treatment practiced by the general medical community.
      d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
      e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment
   Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:
      (i) The service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
      (ii) The service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
      (iii) The service or benefit will assist the Member to achieve or maintain maximum functional
capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.

DESCRIPTION:
Convolution-enhanced drug delivery (CED) is an innovative drug delivery technique used to circumvent the blood-brain barrier and deliver therapeutic agents directly into the parenchyma. CED uses a pressure gradient established at the tip of an infusion catheter that creates a bulk flow, which “pushes” the drug in the extracellular space. As a result, the drug is thought to be distributed more evenly, at higher concentrations, and over a large area.

EXCLUSIONS:
The Plan does NOT provide coverage for the use of Convolution-enhanced Drug Delivery into the parenchyma of the brain for any indication because it is considered experimental, investigational or unproven. There is insufficient evidence in the peer-reviewed published medical literature to establish the safety and effectiveness of this treatment on health outcomes when compared to established treatments or technologies.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH: Convolution-enhanced Drug Delivery
The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

41019 Placement of needles, catheters, or other device(s) into the head and/or neck region (percutaneous, transoral, or transnasal) for subsequent interstitial radionuclide application

REFERENCES:


Patel MM, Patel BM. Crossing the blood-brain barrier: Recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109-133.


NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (V1.2019).

This policy will be revised as necessary and reviewed no less than annually.

Devised: 12/2006

Revised: 3/08 (coding); 3/09